Skip to main content
Premium Trial:

Request an Annual Quote

Richard Barker, Thomas Vogel, James Meade, Paul Young


Richard Barker has become executive chairman of the board of directors of New Haven, Conn.-based Molecular Staging. Previously, he was CEO of Chiron Diagnostics and general manager of IBM’s health care solutions business. Before that, he led the pharmaceutical practice in Europe for McKinsey. Barker holds a BA in chemistry and a doctorate in biophysics from the University of Oxford in England.

Thomas Vogel has been appointed to the Board of Directors and the Audit and Compensation Committee of Boston Biomedica, as part of the Board’s expansion. Vogel is the president and CEO of the drug discovery company AdipoGenix. Prior to that, he was CEO and director of Mosaic Technologies and founder of venture capital firm Charlestown Group. At various times previously he has served as president of Fisher Scientific, president of PB Diagnostics, president of Instrumentation Laboratory, and president of Serono Diagnostics. He has also served as divisional vice president and general manager of diagnostic products at Abbott Laboratories. Vogel holds a bachelor’s degree in electrical engineering from the Georgia Institute of Technology and an MBA from Wharton Business School.

James Meade has been named vice president of business development at Avalon Pharmaceuticals, and Paul Young has been promoted to vice president of research at the company. Meade comes to Avalon from Pfizer/Pharmacia, where he worked in global licensing of anti-infective and urology products. He has also worked previously at Bayer, Chiron, and Cetus. Young was most recently senior scientific director of discovery biology at Avalon, and a member of its scientific management committee. Prior to that, he worked as a senior scientist at Human Genome Sciences, and previously, at Bayer and Genentech.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.